All stock lists
LifeStance Health Group, Inc. (NASDAQ:LFST)
US · Delayed Price · Currency is USD
Healthcare · Medical - Care Facilities
13.07+0.14 (+1.08%)
Insider Score
––Not scored
LFST Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
LFST analyst forecast
LFST analyst consensus
Moderate Buy5 ratings
Buy 4 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
LFST 12-month price target
$15.00+14.2% upsideaverage of 1 firm
$15.00High
$15.00Low
Best analysts covering LFST
- Barclays100%success rate · 3 calls
- UBS100%success rate · 2 calls
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
LFST analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | Keybanc | Overweight | — | — | Reiterated | 2026-10-05 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-09-10 |
| Canaccord Genuity | Buy | $15.00 | +17.2% | Reiterated | 2026-09-09 | |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-19 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-08-14 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-07 |
| — | BTIG | Buy | — | — | Reiterated | 2026-07-24 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-07-21 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-07-14 |
| — | Keybanc | Overweight | — | — | Reiterated | 2026-07-13 |
| — | Goldman Sachs | Neutral | — | — | Downgraded | 2026-06-05 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2026-05-14 |
| — | BTIG | Buy | — | — | Reiterated | 2026-05-08 |
| — | Barclays | Overweight | — | — | Reiterated | 2026-03-06 |
| — | Canaccord Genuity | Buy | — | — | Reiterated | 2026-02-26 |
| — | Keybanc | Overweight | — | — | Reiterated | 2026-02-26 |
| — | UBS | Buy | — | — | Reiterated | 2026-02-26 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-02 |
| — | BTIG | Buy | — | — | Reiterated | 2025-12-12 |
| — | UBS | Buy | — | — | Reiterated | 2025-11-07 |
| — | BTIG | Buy | — | — | Reiterated | 2025-11-06 |
| — | UBS | Buy | — | — | Reiterated | 2025-08-08 |
| — | UBS | Buy | — | — | Upgraded | 2025-05-27 |
| — | Goldman Sachs | Buy | — | — | Upgraded | 2024-12-16 |
| — | Barclays | Underweight | — | — | Reiterated | 2024-11-11 |
| — | UBS | Neutral | — | — | Reiterated | 2024-08-15 |
| — | Barclays | Underweight | — | — | Reiterated | 2024-08-09 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2024-04-22 |
| — | Jefferies | Buy | — | — | Reiterated | 2024-03-06 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2024-03-04 |
| — | Barclays | Underweight | — | — | Reiterated | 2024-02-29 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2023-11-22 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2023-11-17 |
| — | JP Morgan | Neutral | — | — | Reiterated | 2023-08-10 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-07-13 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2023-05-19 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2023-05-11 |
| — | Morgan Stanley | Overweight | — | — | Upgraded | 2023-01-06 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-11-15 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2022-11-14 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2022-08-22 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2022-05-10 |
| — | Goldman Sachs | Neutral | — | — | Reiterated | 2022-03-21 |
| — | UBS | Neutral | — | — | Downgraded | 2022-03-17 |
| — | Morgan Stanley | Equal Weight | — | — | Reiterated | 2021-12-17 |
| — | JP Morgan | Neutral | — | — | Downgraded | 2021-11-09 |
| — | Cowen & Co. | Outperform | — | — | Reiterated | 2021-09-10 |
| — | Morgan Stanley | Equal Weight | — | — | Downgraded | 2021-08-16 |
| — | UBS | Buy | — | — | Reiterated | 2021-07-06 |
| — | William Blair | Outperform | — | — | Reiterated | 2021-07-06 |
| — | Morgan Stanley | Overweight | — | — | Reiterated | 2021-07-06 |
LFST earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-25 | -0.00 | 0.03 | $378.4M | $382.2M |
| 2026-05-07 | 0.01 | 0.04 | $387.5M | $403.5M |
| 2026-08-06 | 0.03 | 0.06 | $414.6M | $435.4M |
| 2026-11-05 | 0.04 | 0.00 | $431.6M | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.